Barrack Obama and Dr. Sullivan's Watch…..
"Dr. Sullivan’s long-term commitment to Ebola research has resulted in discovery of both vaccines and therapies. By using a novel gene-based prime boost vaccine, Dr. Sullivan and her team were the first to demonstrate vaccine protection against Ebola infection in primates. This was followed by her discovery of a single shot vaccine that provided more immediate protection, making it a very practical vaccine that could be used in the face of an acute Ebola epidemic. As a result, this vaccination schedule is now standard in the field of Ebola vaccine research, where one of the lead Ebola vaccine candidates, ChAd3-EBOV, has been advanced to Phase I/II and III human clinical trials. More recently, Dr. Sullivan and her team discovered a potently protective monoclonal antibody, mAb114, from a human Ebola survivor that completely rescues Ebola-infected primates, even when given as a monotherapy several days after their Ebola exposure. Studies with the antibody demonstrated that the most potent mechanism of antibody protection is through high affinity, low pH-stable binding that blocks a critical Ebola interaction with its intracellular receptor, Neimann-Pick C1. This antibody will undergo Phase I clinical trials in 2017 to support stockpiling in preparation for use in future Ebola outbreaks."
https://www.niaid.nih.gov/research/nancy-sullivan-phd
Western African Ebola virus epidemic
2013–2016 major outbreak of Ebola virus disease mainly in Guinea, Liberia and Sierra Leone
Western African Ebola virus epidemic
The Western African Ebola virus epidemic (2013–2016) was the most widespread outbreak of Ebola virus disease (EVD) in history, causing major loss of life and socioeconomic disruption in the region, mainly in Guinea, Liberia and Sierra Leone. The first cases were recorded in Guinea in December 2013; later, the disease spread to neighbouring Liberia and Sierra Leone, with minor outbreaks occurring elsewhere. It caused significant mortality, with the case fatality rate reported which was initially considerable, while the rate among hospitalised patients was 57–59%, the final numbers 28,616 people, including 11,310 deaths, for a case-fatality rate of 40%. Small outbreaks occurred in Nigeria and Mali, and secondary infections of medical workers occurred in the United States and Spain. In addition, isolated cases were recorded in Senegal, the United Kingdom and Italy. The number of cases peaked in October 2014 and then began to decline gradually, following the commitment of substantial international resources. As of 8 May 2016, the World Health Organization (WHO) and respective governments reported a total of 28,646 suspected cases and 11,323 deaths (39.5%), though the WHO believes that this substantially understates the magnitude of the outbreak.
https://en.wikipedia.org/wiki/Western_African_Ebola_virus_epidemic